Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06219980
Other study ID # B2023-278-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 7, 2023
Est. completion date December 7, 2026

Study information

Verified date March 2024
Source Sun Yat-sen University
Contact Fang-Yun Xie
Phone +862087342926
Email xiefy@sysucc.org.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In resectable locally advanced oral cavity cancer and oropharyngeal cancer, SBRT with the total dose of 18 Gy by three fractions will be delivered to the primary tumor and metastatic lymph nodes every other day. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics. The investigators aim to evaluate the pathological complete response rate and safety of the combined treatment of SBRT with chemoimmunotherapy in locally advanced cancers of oral cavity and oropharynx.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date December 7, 2026
Est. primary completion date December 7, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - pathologically confirmed squamous carcinoma of oral cavity or oropharynx - III-IVa based on the eighth edition of AJCC - aged 18 to 70 - ECOG PS 0-1 - no organ dysfunction - Expected survival = 3 months Exclusion Criteria: - diagnosed with other malignant tumors - has autoimmune diseases or serious mental illness - at high risk of hemorrhage - Systemic or local glucocorticoid therapy within 4 weeks - Comorbidities requiring long-term treatment with immunosuppressive drugs or systemic or topical corticosteroids in immunosuppressive doses - Patients with active tuberculosis (TB) who are receiving anti-tuberculosis treatment or have received anti-tuberculosis treatment within 1 year prior to screening. - Prior use of anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, or anti-CTLA-4 antibody - HIV or HCV - HBsAg positive with positive HBV DNA copy number (quantitative test) =1000cps/ml

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
SBRT+chemoimmunotherapy
All eligible patients will receive SBRT (6Gy*3 fractions, qod) to the primary site and metastatic lymph nodes. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics.

Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

References & Publications (2)

Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A, Samedi V, Bubak A, Greene C, Waxweiler T, Mehrotra S, Bhatia S, Gadwa J, Bickett T, Piper M, Fakhoury K, Liu A, Petit J, Bowles D, Thaker A, Atiyeh K, Goddard J, Hoyer R, Van Bokhoven A, Jordan K, Jimeno A, D'Alessandro A, Raben D, McDermott JD, Karam SD. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer. 2022 Nov;3(11):1300-1317. doi: 10.1038/s43018-022-00450-6. Epub 2022 Nov 25. Erratum In: Nat Cancer. 2023 Jan;4(1):148. Nat Cancer. 2024 Jan;5(1):210. — View Citation

Ma TM, Wong DJ, Chai-Ho W, Mendelsohn A, St John M, Abemayor E, Chhetri D, Sajed D, Dang A, Chu FI, Xiang M, Savjanji R, Weidhaas J, Steinberg ML, Cao M, Kishan AU, Chin RK. High Recurrence for HPV-Positive Oropharyngeal Cancer With Neoadjuvant Radiation Therapy to Gross Disease Plus Immunotherapy: Analysis From a Prospective Phase Ib/II Clinical Trial. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):348-354. doi: 10.1016/j.ijrobp.2023.04.029. Epub 2023 May 2. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary rate of pathological complete response pathological complete response rate after radical resection immediately after the surgery
Secondary rate of major pathological response immediately after the surgery
Secondary objective response rate two weeks after the chemoimmunotherapy
Secondary disease free survival 3-year
Secondary overall survival 3-year
Secondary rate of adverse events one month after the postoperative radiotherapy
See also
  Status Clinical Trial Phase
Terminated NCT04476797 - Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC Phase 1/Phase 2
Not yet recruiting NCT04587817 - Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors
Active, not recruiting NCT04067570 - Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer N/A
Recruiting NCT02976402 - Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy Phase 1
Not yet recruiting NCT02940990 - SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations Phase 2
Terminated NCT04698915 - Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer Phase 2
Active, not recruiting NCT05817604 - Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
Active, not recruiting NCT04942275 - Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy Phase 2/Phase 3
Recruiting NCT04547452 - Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC Phase 2
Completed NCT03891472 - Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer Phase 2
Recruiting NCT05344235 - Observational Study on Extreme Hypofractionation for Localized Prostate Cancer